DETAILS, FICTION AND PAOPA

There were no clinically important distinctions within the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when used concomitantly with finerenone. Various doses of 40 mg finerenone at the time-everyday experienced no clinically related impact on AUC or Cmax from the BCRP and OATP substrate rosuvastatin.S